Replimune Group Yönetim

Yönetim kriter kontrolleri 2/4

Replimune Group CEO'su Sush Patel, Apr2024 tarihinde atandı, in görev süresi 1.08 yıldır. şirketin hisselerinin 0.082% doğrudan sahiptir ve bu hisselerin değeri $ 615.67K dir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 1.1 yıl ve 4.3 yıldır.

Anahtar bilgiler

Sush Patel

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	1.1yrs
CEO sahipliği	0.08%
Yönetim ortalama görev süresi	1.1yrs
Yönetim Kurulu ortalama görev süresi	4.3yrs

Son yönetim güncellemeleri

Recent updates

Replimune Group, Inc. (NASDAQ:REPL) Shares Could Be 23% Below Their Intrinsic Value Estimate

Jun 24

We're Not Very Worried About Replimune Group's (NASDAQ:REPL) Cash Burn Rate

Apr 04

Companies Like Replimune Group (NASDAQ:REPL) Are In A Position To Invest In Growth

Dec 16

CEO Tazminat Analizi

Sush Patel'un ücretlendirmesi Replimune Group'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Dec 31 2024	n/a	n/a	-US$228m
Sep 30 2024	n/a	n/a	-US$213m
Jun 30 2024	n/a	n/a	-US$220m
Mar 31 2024	n/a	n/a	-US$216m
Dec 31 2023	n/a	n/a	-US$210m
Sep 30 2023	n/a	n/a	-US$199m
Jun 30 2023	n/a	n/a	-US$182m
Mar 31 2023	US$3m	US$447k	-US$174m
Dec 31 2022	n/a	n/a	-US$157m
Sep 30 2022	n/a	n/a	-US$147m
Jun 30 2022	n/a	n/a	-US$133m
Mar 31 2022	US$7m	US$394k	-US$118m

Tazminat ve Piyasa: Sush şirketinin toplam tazminatının US pazarındaki benzer büyüklükteki şirketlerle karşılaştırıldığında makul olup olmadığını tespit etmek için yeterli veri yok.

Tazminat ve Kazançlar: Sush 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Sush Patel (53 yo)

1.1yrs

Görev süresi

US$2,595,003

Tazminat

Dr. Sushil Patel, also known as Sush,Ph D, is CEO & Director of Replimune Group, Inc. from April 1, 2024. Dr. Patel served as the Chief Commercial Officer at Replimune Group, Inc. since May 3, 2021 and ser...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Philip Astley-Sparke	Executive Chairman	10.3yrs	US$6.02m	1.65% $ 12.5m
Emily Hill	Chief Financial Officer	1.7yrs	US$3.61m	0.015% $ 116.3k
Konstantinos Xynos	Chief Medical Officer	2.4yrs	US$2.45m	0.048% $ 361.5k
Sushil Patel	CEO & Director	1.1yrs	US$2.60m	0.082% $ 615.7k
Andrew Schwendenman	Chief Accounting Officer & Treasurer	2yrs	Veri yok	0.0091% $ 68.6k
Shawn Glidden	Senior Vice President of General Counsel	less than a year	Veri yok	Veri yok
Camilo Garcia	Chief Human Resource Officer	less than a year	Veri yok	Veri yok
Christopher Sarchi	Chief Commercial Officer	2.4yrs	Veri yok	0.027% $ 200.0k
Paul Bullock	Chief Manufacturing Officer & Framingham Site Head	1.3yrs	Veri yok	Veri yok
Nina Aragam	Senior Vice President of Portfolio Strategy & Program Management	less than a year	Veri yok	Veri yok
Carolyn Trott	Senior Vice President of Quality Assurance	1.1yrs	Veri yok	Veri yok
Kari Jeschke	Senior Vice President of Regulatory Affairs	less than a year	Veri yok	Veri yok

1.1yrs

Ortalama Görev Süresi

53yo

Ortalama Yaş

Deneyimli Yönetim: REPL 'un yönetim ekibi deneyimli olarak kabul edilmiyor ( 1.1 yıl), bu da yeni bir ekibin varlığını gösteriyor.

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Philip Astley-Sparke	Executive Chairman	10.3yrs	US$6.02m	1.65% $ 12.5m
Sushil Patel	CEO & Director	1.1yrs	US$2.60m	0.082% $ 615.7k
Joseph Slattery	Independent Director	7.6yrs	US$362.60k	0.0087% $ 65.2k
Michael Goller	Director	less than a year	Veri yok	Veri yok
Paolo Pucci	Independent Director	5.1yrs	US$360.10k	0% $ 0
Madhavan Balachandran	Director	less than a year	Veri yok	Veri yok
Kapil Dhingra	Independent Director	7.8yrs	US$357.60k	0% $ 0
Christy Oliger	Independent Director	3.4yrs	US$352.60k	0% $ 0
Dieter Weinand	Lead Independent Director	6.9yrs	US$516.81k	0% $ 0
Veleka Peeples-Dyer	Independent Director	1.9yrs	US$667.97k	0% $ 0

4.3yrs

Ortalama Görev Süresi

56.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: REPL 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 4.3 yıldır).

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2025/05/01 15:06
Gün Sonu Hisse Fiyatı	2025/05/01 00:00
Kazançlar	2024/12/31
Yıllık Kazançlar	2024/03/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Replimune Group, Inc. 13 Bu analistlerden 4, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Peter Lawson	Barclays
Clarence Powell	BMO Capital Markets Equity Research
Evan Seigerman	BMO Capital Markets Equity Research

Replimune Group Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Replimune Group, Inc. Appoints Michael Goller to Its Board of Directors

CEO & Director notifies of intention to sell stock

Chief Financial Officer recently sold US$91k worth of stock

Replimune Group, Inc., Annual General Meeting, Sep 04, 2024

Chief Medical Officer notifies of intention to sell stock

Executive Chairman recently sold US$245k worth of stock

Recent updates

Replimune: Scope Goes Beyond That Of RP1 Oncolytic Targeting For Melanoma

Is Replimune Group (NASDAQ:REPL) A Risky Investment?

Replimune Group, Inc. Appoints Michael Goller to Its Board of Directors

Replimune: A Misunderstood Contender In Oncolytics

Replimune Group, Inc. Announces Biologics License Application Acceptance and Priority Review for RP1 for the Treatment of Advanced Melanoma

New major risk - Shareholder dilution

Replimune Announces RP2 Development Program Advances with First Patients Enrolled in Metastatic Uveal Melanoma and Hepatocellular Carcinoma Clinical Trials

Price target increased by 11% to US$18.38

CEO & Director notifies of intention to sell stock

Replimune: RPL1 BLA Submission Under AA Pathway Makes It A Must Watch

Replimune Group, Inc. has completed a Follow-on Equity Offering in the amount of $139.999007 million.

Replimune Group, Inc. has filed a Follow-on Equity Offering in the amount of $125 million.

Replimune Group (NASDAQ:REPL) Has Debt But No Earnings; Should You Worry?

New minor risk - Share price stability

Replimune Group, Inc. Receives Breakthrough Therapy Designation for RP1 and Submits RP1 Biologics License Application to the FDA under the Accelerated Approval Pathway

Replimune Presents Late-Breaking Abstract Featuring Data from Ignyte Clinical Trial of Rp1 Combined with Nivolumab in Anti-Pd1 Failed Melanoma At the 39Th Annual Meeting of the Society for Immunotherapy of Cancer (Sitc 2024)

Replimune Presents Primary Analysis Data from IGNYTE Clinical Trial of RP1 Combined with Nivolumab in Anti-Pd1 Failed Melanoma At European Society for Medical Oncology Congress 2024

Replimune: Strong Data In A Highly Differentiated Space

Chief Financial Officer recently sold US$91k worth of stock

Is Replimune Group (NASDAQ:REPL) Using Debt Sensibly?

Consensus revenue estimates decrease by 50%, EPS upgraded

Replimune Group, Inc. Announces First Patient Dosed in IGNYTE-3 Clinical Trial in Advanced Melanoma

Price target increased by 8.2% to US$14.67

Replimune Group, Inc., Annual General Meeting, Sep 04, 2024

Replimune Group, Inc. announced that it expects to receive $100.000032 million in funding

Chief Medical Officer notifies of intention to sell stock

Price target increased by 9.2% to US$14.56

Replimune Group, Inc. Announces Positive Topline Primary Analysis Data by Independent Central Review from IGNYTE Clinical Trial of Rp1 Plus Nivolumab in Anti-Pd1 Failed Melanoma

New minor risk - Share price stability

Replimune Presents Positive Data from Rp1 and Rp2 Clinical Programs At the 2024 American Society of Clinical Oncology (Asco) Annual Meeting

Replimune: Continuing To Justify The Bear Thesis (For Now)

Executive Chairman recently sold US$245k worth of stock

Replimune Group, Inc. Announces Management Changes

Replimune Group (NASDAQ:REPL) Has Debt But No Earnings; Should You Worry?

Replimune: The Fall Is Justified, As Virus Therapy Fails Again In Cancer

Now 21% undervalued after recent price drop

Now 21% undervalued after recent price drop

Calculating The Intrinsic Value Of Replimune Group, Inc. (NASDAQ:REPL)

Now 25% undervalued after recent price drop

Price target decreased by 64% to US$17.22

New minor risk - Share price stability

Replimune Group, Inc. Shares Initial Primary Analysis Results from CERPASS Clinical Trial in Advanced Cutaneous Squamous Cell Carcinoma and Presents New Data from IGNYTE Clinical Trial of RP1 in Anti-PD1 Failure Melanoma and Non-Melanoma Skin Cancers

Chief Medical Officer recently sold US$80k worth of stock

Replimune Group, Inc. Announces the Appointment of Emily Hill as Chief Financial Officer

New major risk - Revenue and earnings growth

Replimune Group, Inc Announces Appointment of Emily Hill as Chief Financial Officer

Chief Business Officer exercised options and sold US$250k worth of stock

Replimune Group, Inc. has completed a Follow-on Equity Offering in the amount of $6.7 million.

Replimune Group, Inc., Annual General Meeting, Sep 06, 2023

Replimune Group, Inc. Announces Sander Slootweg Will Depart from Its Board of Directors

Is Replimune Group (NASDAQ:REPL) A Risky Investment?

Chief Business Officer notifies of intention to sell stock

Chief Strategy Officer notifies of intention to sell stock

Replimune Group, Inc. Appoints Veleka R. Peeples-Dyer to Its Board of Directors

Replimune Group, Inc. Presents RP1 Data from the IGNYTE Anti-PD1 Failure Melanoma Cohort and RP2 Data in Uveal Melanoma at the 2023 American Society of Clinical Oncology Annual Meeting

Consensus revenue estimates fall by 42%

CEO & Director recently sold US$323k worth of stock

No longer forecast to breakeven

Insufficient new directors

Is Replimune Group (NASDAQ:REPL) Using Debt In A Risky Way?

A Look At The Fair Value Of Replimune Group, Inc. (NASDAQ:REPL)

Replimune Group, Inc. Announces Executive Appointments

Chief Business Officer exercised options and sold US$360k worth of stock

Price target increased to US$48.89

Replimune secures $200M term loan

Replimune: Recent Developments Strengthen Bull Thesis

Replimune Group (NASDAQ:REPL) Has Debt But No Earnings; Should You Worry?

Replimune Group GAAP EPS of -$0.78 misses by $0.15

Replimune Group, Inc. (NASDAQ:REPL) Shares Could Be 23% Below Their Intrinsic Value Estimate